EP2242844A2
Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
Abstract
This record has no abstract on file.
Term
Projected expiry 22 December 2028.
- Priority
- Filed
- Published
- Today
- Projected expiry
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP4491184A2 | Cited by | European Patent Office (EPO) | Applicant |
| WO2016029191A2 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| US10465188B2 | Cited by | United States of America | Applicant |
| US11401516B2 | Cited by | United States of America | Applicant |
| See references of WO 2009085271A3 | Non-patent | – | Search report |
8 members in 7 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 8834P | United States of America | – | |
| 883407 | United States of America | P | |
| 2008014022 | United States of America | W |
Members8
| Document | Office | Kind | |
|---|---|---|---|
| AU2008343842A1 | Australia | A1 | |
| CA2710382A1 | Canada | A1 | |
| WO2009085271A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2009085271A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP2242844A2This record | European Patent Office (EPO) | A2 | |
| JP2011507858A | Japan | A | |
| ZA201005218B | South Africa | B | |
| US2011243964A1 | United States of America | A1 |
9 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Application deemed to be withdrawnWithdrawn18D | 18D | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA | STAA | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | |
| First examination report despatched17Q | 17Q | |
| Request for extension of the european patent (deleted)DAX | DAX | |
| Request for examination filed17P | 17P | |
| Designated contracting statesAK | AK | |
| Request for extension of the european patentAX | AX | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 2242844
- Application
- 88688932
Titles3
- German
- VERWENDUNG VON ANTI-CONNEXIN-PEPTIDEN ALLEIN ODER IN KOMBINATION MIT ANTI-CONNEXIN-POLYNUKLEOTIDEN ZUR BEHANDLUNG ORTHOPÄDISCHER LEIDEN
- English
- USE OF ANTI-CONNEXIN PEPTIDES, ALONE OR IN COMBINATION WITH ANTI-CONNEXIN POLYNUCLEOTIDES, FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS
- French
- UTILISATION DE PEPTIDES ANTI-CONENXINES, SEULS OU COMBINÉS À DES POLYNUCLÉOTIDES ANTI-CONNEXINE, POUR LE TRAITEMENT DES MALADIES ORTHOPÉDIQUES
Classification
- CPC, 18
- A61K38/177
- A61K9/0014
- A61K9/0019
- A61K9/06
- A61K9/08
- A61K47/10
- A61K47/14
- A61K47/186
- A61K47/26
- A61K47/34
- A61K47/38
- A61P9/00
- A61P19/02
- A61P29/00
- A61P41/00
- C12N15/1138
- C12N2310/11
- C12N2320/31
- IPC, 4
- A61K38 17
- A61P41 00
- C12N15 113
- C12N15 11
Designated states38
- Contracting states, 34
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Croatia
- Hungary
- Ireland
- Iceland
- Italy
- Liechtenstein
- Lithuania
- Luxembourg
- Latvia
- Monaco
and 10 moreShow fewer
- Malta
- Netherlands (Kingdom of the)
- Norway
- Poland
- Portugal
- Romania
- Sweden
- Slovenia
- Slovakia
- Türkiye
- Extension states, 4
- Albania
- Bosnia and Herzegovina
- North Macedonia
- Serbia